Pharmacological Management of Borderline Personality Disorder and Common Comorbidities.
- Published in:
- CNS Drugs, 2023, v. 37, n. 6, p. 489, doi. 10.1007/s40263-023-01015-6
- By:
- Publication type:
- Article
Works matching IS 11727047 AND DT 2023 AND VI 37 AND IP 6
Results: 6
1
2
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy.
- Published in:
- CNS Drugs, 2023, v. 37, n. 6, p. 531, doi. 10.1007/s40263-023-01013-8
- By:
- Publication type:
- Article
3
Clonazepam Loading Dose in Status Epilepticus: Is More Always Better?
- Published in:
- CNS Drugs, 2023, v. 37, n. 6, p. 523, doi. 10.1007/s40263-023-01012-9
- By:
- Publication type:
- Article
4
Calcitonin in the Treatment of Phantom Limb Pain: A Systematic Review.
- Published in:
- CNS Drugs, 2023, v. 37, n. 6, p. 513, doi. 10.1007/s40263-023-01010-x
- By:
- Publication type:
- Article
5
Early Non-Response to Antipsychotic Treatment in Schizophrenia: A Systematic Review and Meta-Analysis of Evidence-Based Management Options.
- Published in:
- CNS Drugs, 2023, v. 37, n. 6, p. 499, doi. 10.1007/s40263-023-01009-4
- By:
- Publication type:
- Article
6
Andexanet Alfa to Reverse the Effect of Factor Xa Inhibitors in Intracranial Hemorrhage.
- Published in:
- CNS Drugs, 2023, v. 37, n. 6, p. 477, doi. 10.1007/s40263-023-01006-7
- By:
- Publication type:
- Article